Loss of confidence in diabetes management

Managed Care

Volumn 17, Issue 10, 2008, Pages

  Salber, Patricia R ^a   Bestermann, William ^b   Schwartz, Stanley ^c   Marchetti, Albert ^d   Ngai, Jackie ^e  

^a PRS Healthcare Consulting   (United States)

^b Vascular Medicine Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Med ERA   (United States)

^e Radical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 57349086326     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (25)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2006;29 (Suppl 1)S4-S42.
2. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254-8.
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
4. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005;54:1615-1625.
5. Brunzell JD et al. Dyslipidemia of central adiposity and insulin resistance. Diabetes Care. 1999;22 (suppl 3):C10-C13.
6. Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004;27:1647-53.
7. DeFronzo, R. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;23:667-87.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001; 285:2486-97.
9. Fendrick AM, Chernew ME. Value-based insurance design: aligning incentives to bridge the divide between quality improvement and cost containment. Am J Managed Care. 2006;12:1-7.
10. Goke B. Type 2 diabetes: are current oral treatment options sufficient? Exp Clin Endocrinol Diabetes. 2000;108(suppl 2):S243-9.
11. Goldberg RB, Kendall DM, Deeg MA, et al, for the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-54.
12. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol. 2002;90 (suppl):3G-10G.
13. Grundy SM, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-239.
14. Guan YF, et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nature Med. 2005;11:861-6.
15. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc. 2007;298:1180-1188.
16. Maedler K, Carr RD, Bosco D, et al. Sulfonylureas induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metabol. 2005;90:501-6.
17. National Diabetes Information Clearinghouse; http://diabetes.niddk-nih.gov/dm/pubs/statistics/index.htm.
18. Freudenheim M. Some employers are offering free drugs. New York Times, Feb 21,2007, A1.
19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.
20. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long term clinical outcomes, costs, and cost-effectiveness in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin. 2004;20 (suppl 1):S5-S26.
21. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20 (suppl 1):S27-S40.
22. Polonsky KS, et al. Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334:777-83.
23. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. J Am Med Assoc. 2007;298:1189-1195.
24. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89-94.
25. Zhang et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci. 2005;102:9406-11.